Kefah Mokbel, Chair of Breast Cancer Surgery at London Breast Institute and Honorary Professor of Medicine at Cardiff University School of Medicine, shared a post on LinkedIn:
“GLP-1 Drugs Such as Mounjaro Show Promise in Breast Cancer: GLP-1 receptor agonists may have a role beyond weight loss and glycaemic control in breast cancer care.
A major new cohort study published in JAMA Network Open analysed data from 841,831 women with breast cancer and found that GLP-1 receptor agonist use was associated with significantly improved survival and lower recurrence rates in patients with obesity and type 2 diabetes.
Among patients with obesity, GLP-1 RA use was associated with:
- 65% lower all-cause mortality
- 56% lower recurrence risk
The findings add to the growing evidence linking metabolic health to breast cancer outcomes and support the urgent need for prospective randomised clinical trials evaluating GLP-1 receptor agonists in oncology. This could represent an important step toward integrating metabolic therapy into personalised breast cancer management.
Comments
- These findings reinforce the growing link between metabolic health and breast cancer outcomes, while highlighting the urgent need for prospective randomised trials before GLP-1 RAs can be integrated into routine oncologic practice.
- Although causality cannot be established from retrospective data, this large real-world study raises the possibility that GLP-1 receptor agonists may emerge as an important adjunct in personalised breast cancer care.
- The study adds to emerging evidence that targeting metabolic dysfunction may influence breast cancer outcomes, opening an important avenue for future translational and clinical research.”
Title: Survival and Recurrence With GLP-1 Receptor Agonists in Breast Cancer
Authors: Kristina L. Tatum, Bassam Dahman, Aniyah Stevenson, Sarah E. Williford, J. Brian Cassel, Hua Zhao, Jie Shen, Kandace P. McGuire, Obinna Diala, Racheal Oladimeji, W. Greg Hundley, Bernard F. Fuemmeler
Read the Full Article.
Other articles about GLP-1 Receptor Agonists on OncoDaily.